stockchase picture

Compiling comments that experts make about stocks while on public TV.

2012-11-30

Opinion for Abbott Labs (ABT-N)

Signal Price Bias Subject Owned
$65.000 CAUTIOUS NORTH AMERICAN - LARGE Yes

Splitting as of Jan 2nd.  Trading ‘as is’ in December.  ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks.  Thinks there is more upside in the Drug exploration part.  Humera is one of the 5 biggest drugs globally.  5 drugs in clinical trials.  A really good pipeline. 

Chyanne Fickes
Vice President of Investments, Stone Funds

No Comments.


You must be logged in to comment.